Pfizer Inc. (NYSE:PFE) Shares Acquired by Lifeworks Advisors LLC

Lifeworks Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 195,440 shares of the biopharmaceutical company’s stock after purchasing an additional 8,544 shares during the period. Pfizer comprises about 1.1% of Lifeworks Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. Lifeworks Advisors LLC’s holdings in Pfizer were worth $5,656,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Addison Advisors LLC lifted its stake in Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock worth $1,512,000 after purchasing an additional 41,668 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Pfizer by 4.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company’s stock worth $379,657,000 after purchasing an additional 544,418 shares during the period. LGT Group Foundation lifted its position in shares of Pfizer by 2.5% in the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after buying an additional 18,274 shares during the last quarter. Radnor Capital Management LLC bought a new stake in shares of Pfizer during the 3rd quarter valued at about $2,972,000. Finally, Kornitzer Capital Management Inc. KS raised its stake in Pfizer by 2.4% during the third quarter. Kornitzer Capital Management Inc. KS now owns 1,168,315 shares of the biopharmaceutical company’s stock worth $33,811,000 after acquiring an additional 27,562 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.22 on Thursday, hitting $26.50. The company had a trading volume of 5,019,627 shares, compared to its average volume of 37,629,043. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $150.18 billion, a PE ratio of 36.11, a PEG ratio of 0.83 and a beta of 0.67. The business has a 50-day simple moving average of $28.76 and a 200-day simple moving average of $28.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company posted ($0.17) EPS. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.34%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Barclays increased their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.